J&J Appoints Thibaut Mongon CEO of New Consumer Health Company

Johnson & Johnson recently appointed Thibaut Mongon as chief executive officer and Paul Ruh as chief financial officer designate of its future consumer health company.  

With over 20 years of global experience at Johnson & Johnson, Mongon has served as executive vice president and worldwide chairman of consumer health at Johnson & Johnson since 2019. Throughout his time at the company, Mongon has helped unlock significant value through external partnerships and strategic acquisitions. 

Paul Ruh is a global financial executive with deep expertise in the consumer-packaged-goods (CPG) industry. He joined Johnson & Johnson five years ago to become the CFO of the consumer health business.   

The planned separation, first announced in November 2021, would create two global leaders — the new Johnson & Johnson and the new consumer health company — that are better positioned to deliver improved health outcomes for patients and consumers through innovation, pursue more targeted business strategies, and boost growth.  

The company would be the leading global consumer health company, helping consumers globally through brands such as Neutrogena, Aveeno, Tylenol, Listerine, Johnson’s, and BAND-AID.  

Alex Gorsky, executive chairman of Johnson & Johnson, stated that he couldn’t be more pleased to announce the appointment of Thibaut as CEO of Designate.  

“Under his leadership, the Consumer Health business of Johnson & Johnson has advanced its innovation to reach consumers with products that truly make a difference in their personal health, while simultaneously delivering healthy financial results,” Gorsky said in the recent announcement. 

“Having worked with both Thibaut and Paul for many years, and, after conducting a thorough external search, I am confident in their collective ability to lead the New Consumer Health Company and its portfolio of iconic brands into the future as a standalone company. I look forward to our continued partnership as the company continues to work towards the planned separation,” he continued.  

Following the planned separation, Johnson & Johnson would remain the world’s largest and most diverse healthcare company and continue its commitment to lead in global healthcare R&D and innovation 

This leadership transition will occur upon completion of the planned separation of the Consumer Health business, expected to occur within 2023.